nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanabenz—Malnutrition—Sorafenib—liver cancer	0.004	0.00458	CcSEcCtD
Guanabenz—Erythema—Sorafenib—liver cancer	0.004	0.00458	CcSEcCtD
Guanabenz—Ageusia—Doxorubicin—liver cancer	0.00386	0.00442	CcSEcCtD
Guanabenz—Muscle spasms—Sorafenib—liver cancer	0.00385	0.00441	CcSEcCtD
Guanabenz—Skin discolouration—Epirubicin—liver cancer	0.00375	0.00429	CcSEcCtD
Guanabenz—Anaemia—Sorafenib—liver cancer	0.0037	0.00423	CcSEcCtD
Guanabenz—Hypocalcaemia—Epirubicin—liver cancer	0.0037	0.00423	CcSEcCtD
Guanabenz—Thinking abnormal—Epirubicin—liver cancer	0.0037	0.00423	CcSEcCtD
Guanabenz—Oliguria—Epirubicin—liver cancer	0.00367	0.0042	CcSEcCtD
Guanabenz—Angioedema—Sorafenib—liver cancer	0.00366	0.00419	CcSEcCtD
Guanabenz—Syncope—Sorafenib—liver cancer	0.00359	0.00411	CcSEcCtD
Guanabenz—Leukopenia—Sorafenib—liver cancer	0.00358	0.0041	CcSEcCtD
Guanabenz—Bone pain—Epirubicin—liver cancer	0.00353	0.00404	CcSEcCtD
Guanabenz—Loss of consciousness—Sorafenib—liver cancer	0.00352	0.00403	CcSEcCtD
Guanabenz—Cough—Sorafenib—liver cancer	0.00349	0.004	CcSEcCtD
Guanabenz—Inflammation—Epirubicin—liver cancer	0.00349	0.00399	CcSEcCtD
Guanabenz—Skin discolouration—Doxorubicin—liver cancer	0.00347	0.00397	CcSEcCtD
Guanabenz—Hypertension—Sorafenib—liver cancer	0.00345	0.00396	CcSEcCtD
Guanabenz—Musculoskeletal pain—Epirubicin—liver cancer	0.00342	0.00392	CcSEcCtD
Guanabenz—Neck pain—Epirubicin—liver cancer	0.00342	0.00392	CcSEcCtD
Guanabenz—Hypocalcaemia—Doxorubicin—liver cancer	0.00342	0.00392	CcSEcCtD
Guanabenz—Thinking abnormal—Doxorubicin—liver cancer	0.00342	0.00392	CcSEcCtD
Guanabenz—Arthralgia—Sorafenib—liver cancer	0.00341	0.0039	CcSEcCtD
Guanabenz—Myalgia—Sorafenib—liver cancer	0.00341	0.0039	CcSEcCtD
Guanabenz—Oliguria—Doxorubicin—liver cancer	0.0034	0.00389	CcSEcCtD
Guanabenz—Hiccups—Epirubicin—liver cancer	0.00338	0.00387	CcSEcCtD
Guanabenz—Dry mouth—Sorafenib—liver cancer	0.00333	0.00381	CcSEcCtD
Guanabenz—Bone pain—Doxorubicin—liver cancer	0.00327	0.00374	CcSEcCtD
Guanabenz—Infection—Sorafenib—liver cancer	0.00324	0.00371	CcSEcCtD
Guanabenz—Skin exfoliation—Epirubicin—liver cancer	0.00323	0.0037	CcSEcCtD
Guanabenz—Inflammation—Doxorubicin—liver cancer	0.00323	0.00369	CcSEcCtD
Guanabenz—Shock—Sorafenib—liver cancer	0.00321	0.00368	CcSEcCtD
Guanabenz—Nervous system disorder—Sorafenib—liver cancer	0.0032	0.00367	CcSEcCtD
Guanabenz—Thrombocytopenia—Sorafenib—liver cancer	0.0032	0.00366	CcSEcCtD
Guanabenz—Skin disorder—Sorafenib—liver cancer	0.00317	0.00363	CcSEcCtD
Guanabenz—Neck pain—Doxorubicin—liver cancer	0.00317	0.00363	CcSEcCtD
Guanabenz—Musculoskeletal pain—Doxorubicin—liver cancer	0.00317	0.00363	CcSEcCtD
Guanabenz—Hiccups—Doxorubicin—liver cancer	0.00313	0.00358	CcSEcCtD
Guanabenz—Anorexia—Sorafenib—liver cancer	0.00311	0.00356	CcSEcCtD
Guanabenz—Rash maculo-papular—Epirubicin—liver cancer	0.00307	0.00352	CcSEcCtD
Guanabenz—Pulmonary oedema—Epirubicin—liver cancer	0.00301	0.00345	CcSEcCtD
Guanabenz—Skin exfoliation—Doxorubicin—liver cancer	0.00299	0.00342	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00298	0.00341	CcSEcCtD
Guanabenz—Mental disability—Epirubicin—liver cancer	0.00294	0.00336	CcSEcCtD
Guanabenz—Dyspnoea—Sorafenib—liver cancer	0.00291	0.00333	CcSEcCtD
Guanabenz—Dyspepsia—Sorafenib—liver cancer	0.00287	0.00329	CcSEcCtD
Guanabenz—Rash maculo-papular—Doxorubicin—liver cancer	0.00285	0.00326	CcSEcCtD
Guanabenz—Decreased appetite—Sorafenib—liver cancer	0.00284	0.00325	CcSEcCtD
Guanabenz—Diabetes mellitus—Epirubicin—liver cancer	0.00282	0.00323	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Sorafenib—liver cancer	0.00282	0.00323	CcSEcCtD
Guanabenz—Fatigue—Sorafenib—liver cancer	0.00282	0.00322	CcSEcCtD
Guanabenz—Pain—Sorafenib—liver cancer	0.00279	0.0032	CcSEcCtD
Guanabenz—Constipation—Sorafenib—liver cancer	0.00279	0.0032	CcSEcCtD
Guanabenz—Pulmonary oedema—Doxorubicin—liver cancer	0.00279	0.00319	CcSEcCtD
Guanabenz—Eczema—Epirubicin—liver cancer	0.00273	0.00313	CcSEcCtD
Guanabenz—Mental disability—Doxorubicin—liver cancer	0.00272	0.00311	CcSEcCtD
Guanabenz—Gastrointestinal pain—Sorafenib—liver cancer	0.00267	0.00306	CcSEcCtD
Guanabenz—Diabetes mellitus—Doxorubicin—liver cancer	0.00261	0.00299	CcSEcCtD
Guanabenz—Dermatitis exfoliative—Epirubicin—liver cancer	0.0026	0.00298	CcSEcCtD
Guanabenz—Urticaria—Sorafenib—liver cancer	0.00259	0.00297	CcSEcCtD
Guanabenz—Body temperature increased—Sorafenib—liver cancer	0.00258	0.00296	CcSEcCtD
Guanabenz—Abdominal pain—Sorafenib—liver cancer	0.00258	0.00296	CcSEcCtD
Guanabenz—Dermatitis bullous—Epirubicin—liver cancer	0.00257	0.00294	CcSEcCtD
Guanabenz—Eczema—Doxorubicin—liver cancer	0.00253	0.0029	CcSEcCtD
Guanabenz—Hypoglycaemia—Epirubicin—liver cancer	0.00252	0.00288	CcSEcCtD
Guanabenz—Cardiac failure—Epirubicin—liver cancer	0.00252	0.00288	CcSEcCtD
Guanabenz—Hyponatraemia—Epirubicin—liver cancer	0.00247	0.00282	CcSEcCtD
Guanabenz—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00241	0.00276	CcSEcCtD
Guanabenz—Hypersensitivity—Sorafenib—liver cancer	0.00241	0.00276	CcSEcCtD
Guanabenz—Dermatitis bullous—Doxorubicin—liver cancer	0.00238	0.00272	CcSEcCtD
Guanabenz—Face oedema—Epirubicin—liver cancer	0.00237	0.00271	CcSEcCtD
Guanabenz—Asthenia—Sorafenib—liver cancer	0.00234	0.00268	CcSEcCtD
Guanabenz—Hypoglycaemia—Doxorubicin—liver cancer	0.00233	0.00267	CcSEcCtD
Guanabenz—Cardiac failure—Doxorubicin—liver cancer	0.00233	0.00267	CcSEcCtD
Guanabenz—Pruritus—Sorafenib—liver cancer	0.00231	0.00265	CcSEcCtD
Guanabenz—Dehydration—Epirubicin—liver cancer	0.00228	0.00261	CcSEcCtD
Guanabenz—Hyponatraemia—Doxorubicin—liver cancer	0.00228	0.00261	CcSEcCtD
Guanabenz—Liver function test abnormal—Epirubicin—liver cancer	0.00227	0.0026	CcSEcCtD
Guanabenz—Dry skin—Epirubicin—liver cancer	0.00225	0.00258	CcSEcCtD
Guanabenz—Orthostatic hypotension—Epirubicin—liver cancer	0.00224	0.00257	CcSEcCtD
Guanabenz—Hypokalaemia—Epirubicin—liver cancer	0.00223	0.00256	CcSEcCtD
Guanabenz—Diarrhoea—Sorafenib—liver cancer	0.00223	0.00256	CcSEcCtD
Guanabenz—Breast disorder—Epirubicin—liver cancer	0.00222	0.00254	CcSEcCtD
Guanabenz—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00221	0.00253	CcSEcCtD
Guanabenz—Face oedema—Doxorubicin—liver cancer	0.00219	0.00251	CcSEcCtD
Guanabenz—Gastritis—Epirubicin—liver cancer	0.00217	0.00249	CcSEcCtD
Guanabenz—Dizziness—Sorafenib—liver cancer	0.00216	0.00247	CcSEcCtD
Guanabenz—Abdominal distension—Epirubicin—liver cancer	0.00214	0.00245	CcSEcCtD
Guanabenz—Influenza—Epirubicin—liver cancer	0.00212	0.00243	CcSEcCtD
Guanabenz—Dehydration—Doxorubicin—liver cancer	0.00211	0.00242	CcSEcCtD
Guanabenz—Liver function test abnormal—Doxorubicin—liver cancer	0.0021	0.0024	CcSEcCtD
Guanabenz—Dry skin—Doxorubicin—liver cancer	0.00208	0.00238	CcSEcCtD
Guanabenz—Vomiting—Sorafenib—liver cancer	0.00208	0.00238	CcSEcCtD
Guanabenz—Orthostatic hypotension—Doxorubicin—liver cancer	0.00208	0.00238	CcSEcCtD
Guanabenz—Hypokalaemia—Doxorubicin—liver cancer	0.00207	0.00237	CcSEcCtD
Guanabenz—Rash—Sorafenib—liver cancer	0.00206	0.00236	CcSEcCtD
Guanabenz—Dermatitis—Sorafenib—liver cancer	0.00206	0.00236	CcSEcCtD
Guanabenz—Breast disorder—Doxorubicin—liver cancer	0.00205	0.00235	CcSEcCtD
Guanabenz—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00205	0.00234	CcSEcCtD
Guanabenz—Headache—Sorafenib—liver cancer	0.00205	0.00234	CcSEcCtD
Guanabenz—Gastritis—Doxorubicin—liver cancer	0.00201	0.0023	CcSEcCtD
Guanabenz—Abdominal distension—Doxorubicin—liver cancer	0.00198	0.00226	CcSEcCtD
Guanabenz—Upper respiratory tract infection—Epirubicin—liver cancer	0.00197	0.00226	CcSEcCtD
Guanabenz—Influenza—Doxorubicin—liver cancer	0.00196	0.00225	CcSEcCtD
Guanabenz—Nausea—Sorafenib—liver cancer	0.00194	0.00222	CcSEcCtD
Guanabenz—Weight increased—Epirubicin—liver cancer	0.00193	0.00221	CcSEcCtD
Guanabenz—Weight decreased—Epirubicin—liver cancer	0.00192	0.0022	CcSEcCtD
Guanabenz—Hyperglycaemia—Epirubicin—liver cancer	0.00191	0.00219	CcSEcCtD
Guanabenz—Infestation NOS—Epirubicin—liver cancer	0.00189	0.00217	CcSEcCtD
Guanabenz—Infestation—Epirubicin—liver cancer	0.00189	0.00217	CcSEcCtD
Guanabenz—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00183	0.00209	CcSEcCtD
Guanabenz—Weight increased—Doxorubicin—liver cancer	0.00179	0.00205	CcSEcCtD
Guanabenz—Weight decreased—Doxorubicin—liver cancer	0.00178	0.00203	CcSEcCtD
Guanabenz—Hyperglycaemia—Doxorubicin—liver cancer	0.00177	0.00203	CcSEcCtD
Guanabenz—Infestation NOS—Doxorubicin—liver cancer	0.00175	0.002	CcSEcCtD
Guanabenz—Infestation—Doxorubicin—liver cancer	0.00175	0.002	CcSEcCtD
Guanabenz—Haemoglobin—Epirubicin—liver cancer	0.00171	0.00196	CcSEcCtD
Guanabenz—Haemorrhage—Epirubicin—liver cancer	0.0017	0.00195	CcSEcCtD
Guanabenz—Oedema peripheral—Epirubicin—liver cancer	0.00167	0.00192	CcSEcCtD
Guanabenz—Connective tissue disorder—Epirubicin—liver cancer	0.00167	0.00191	CcSEcCtD
Guanabenz—Erythema multiforme—Epirubicin—liver cancer	0.00161	0.00184	CcSEcCtD
Guanabenz—Eye disorder—Epirubicin—liver cancer	0.00159	0.00182	CcSEcCtD
Guanabenz—Tinnitus—Epirubicin—liver cancer	0.00158	0.00181	CcSEcCtD
Guanabenz—Haemoglobin—Doxorubicin—liver cancer	0.00158	0.00181	CcSEcCtD
Guanabenz—Haemorrhage—Doxorubicin—liver cancer	0.00157	0.0018	CcSEcCtD
Guanabenz—Oedema peripheral—Doxorubicin—liver cancer	0.00155	0.00177	CcSEcCtD
Guanabenz—Connective tissue disorder—Doxorubicin—liver cancer	0.00154	0.00177	CcSEcCtD
Guanabenz—Immune system disorder—Epirubicin—liver cancer	0.00153	0.00176	CcSEcCtD
Guanabenz—Mediastinal disorder—Epirubicin—liver cancer	0.00153	0.00175	CcSEcCtD
Guanabenz—Chills—Epirubicin—liver cancer	0.00152	0.00175	CcSEcCtD
Guanabenz—Erythema multiforme—Doxorubicin—liver cancer	0.00149	0.0017	CcSEcCtD
Guanabenz—Erythema—Epirubicin—liver cancer	0.00148	0.00169	CcSEcCtD
Guanabenz—Malnutrition—Epirubicin—liver cancer	0.00148	0.00169	CcSEcCtD
Guanabenz—Eye disorder—Doxorubicin—liver cancer	0.00147	0.00168	CcSEcCtD
Guanabenz—Tinnitus—Doxorubicin—liver cancer	0.00147	0.00168	CcSEcCtD
Guanabenz—Flatulence—Epirubicin—liver cancer	0.00146	0.00167	CcSEcCtD
Guanabenz—Tension—Epirubicin—liver cancer	0.00145	0.00166	CcSEcCtD
Guanabenz—Nervousness—Epirubicin—liver cancer	0.00144	0.00164	CcSEcCtD
Guanabenz—Back pain—Epirubicin—liver cancer	0.00143	0.00164	CcSEcCtD
Guanabenz—Muscle spasms—Epirubicin—liver cancer	0.00142	0.00163	CcSEcCtD
Guanabenz—Immune system disorder—Doxorubicin—liver cancer	0.00142	0.00163	CcSEcCtD
Guanabenz—Mediastinal disorder—Doxorubicin—liver cancer	0.00142	0.00162	CcSEcCtD
Guanabenz—Chills—Doxorubicin—liver cancer	0.00141	0.00161	CcSEcCtD
Guanabenz—Vision blurred—Epirubicin—liver cancer	0.00139	0.0016	CcSEcCtD
Guanabenz—Ill-defined disorder—Epirubicin—liver cancer	0.00137	0.00157	CcSEcCtD
Guanabenz—Erythema—Doxorubicin—liver cancer	0.00137	0.00157	CcSEcCtD
Guanabenz—Malnutrition—Doxorubicin—liver cancer	0.00137	0.00157	CcSEcCtD
Guanabenz—Anaemia—Epirubicin—liver cancer	0.00137	0.00157	CcSEcCtD
Guanabenz—Agitation—Epirubicin—liver cancer	0.00136	0.00156	CcSEcCtD
Guanabenz—Flatulence—Doxorubicin—liver cancer	0.00135	0.00154	CcSEcCtD
Guanabenz—Tension—Doxorubicin—liver cancer	0.00134	0.00154	CcSEcCtD
Guanabenz—Malaise—Epirubicin—liver cancer	0.00133	0.00153	CcSEcCtD
Guanabenz—Nervousness—Doxorubicin—liver cancer	0.00133	0.00152	CcSEcCtD
Guanabenz—Syncope—Epirubicin—liver cancer	0.00133	0.00152	CcSEcCtD
Guanabenz—Leukopenia—Epirubicin—liver cancer	0.00132	0.00152	CcSEcCtD
Guanabenz—Back pain—Doxorubicin—liver cancer	0.00132	0.00152	CcSEcCtD
Guanabenz—Muscle spasms—Doxorubicin—liver cancer	0.00132	0.00151	CcSEcCtD
Guanabenz—Loss of consciousness—Epirubicin—liver cancer	0.0013	0.00149	CcSEcCtD
Guanabenz—Cough—Epirubicin—liver cancer	0.00129	0.00148	CcSEcCtD
Guanabenz—Vision blurred—Doxorubicin—liver cancer	0.00129	0.00148	CcSEcCtD
Guanabenz—Hypertension—Epirubicin—liver cancer	0.00128	0.00146	CcSEcCtD
Guanabenz—Ill-defined disorder—Doxorubicin—liver cancer	0.00127	0.00145	CcSEcCtD
Guanabenz—Anaemia—Doxorubicin—liver cancer	0.00126	0.00145	CcSEcCtD
Guanabenz—Chest pain—Epirubicin—liver cancer	0.00126	0.00144	CcSEcCtD
Guanabenz—Myalgia—Epirubicin—liver cancer	0.00126	0.00144	CcSEcCtD
Guanabenz—Arthralgia—Epirubicin—liver cancer	0.00126	0.00144	CcSEcCtD
Guanabenz—Agitation—Doxorubicin—liver cancer	0.00126	0.00144	CcSEcCtD
Guanabenz—Anxiety—Epirubicin—liver cancer	0.00125	0.00144	CcSEcCtD
Guanabenz—Discomfort—Epirubicin—liver cancer	0.00124	0.00142	CcSEcCtD
Guanabenz—Malaise—Doxorubicin—liver cancer	0.00123	0.00141	CcSEcCtD
Guanabenz—Dry mouth—Epirubicin—liver cancer	0.00123	0.00141	CcSEcCtD
Guanabenz—Syncope—Doxorubicin—liver cancer	0.00123	0.00141	CcSEcCtD
Guanabenz—Leukopenia—Doxorubicin—liver cancer	0.00122	0.0014	CcSEcCtD
Guanabenz—Confusional state—Epirubicin—liver cancer	0.00122	0.00139	CcSEcCtD
Guanabenz—Oedema—Epirubicin—liver cancer	0.00121	0.00138	CcSEcCtD
Guanabenz—Loss of consciousness—Doxorubicin—liver cancer	0.0012	0.00138	CcSEcCtD
Guanabenz—Infection—Epirubicin—liver cancer	0.0012	0.00137	CcSEcCtD
Guanabenz—Cough—Doxorubicin—liver cancer	0.00119	0.00137	CcSEcCtD
Guanabenz—Shock—Epirubicin—liver cancer	0.00119	0.00136	CcSEcCtD
Guanabenz—Nervous system disorder—Epirubicin—liver cancer	0.00118	0.00136	CcSEcCtD
Guanabenz—Thrombocytopenia—Epirubicin—liver cancer	0.00118	0.00135	CcSEcCtD
Guanabenz—Hypertension—Doxorubicin—liver cancer	0.00118	0.00135	CcSEcCtD
Guanabenz—Tachycardia—Epirubicin—liver cancer	0.00118	0.00135	CcSEcCtD
Guanabenz—Skin disorder—Epirubicin—liver cancer	0.00117	0.00134	CcSEcCtD
Guanabenz—Chest pain—Doxorubicin—liver cancer	0.00117	0.00133	CcSEcCtD
Guanabenz—Arthralgia—Doxorubicin—liver cancer	0.00117	0.00133	CcSEcCtD
Guanabenz—Myalgia—Doxorubicin—liver cancer	0.00117	0.00133	CcSEcCtD
Guanabenz—Anxiety—Doxorubicin—liver cancer	0.00116	0.00133	CcSEcCtD
Guanabenz—Discomfort—Doxorubicin—liver cancer	0.00115	0.00132	CcSEcCtD
Guanabenz—Anorexia—Epirubicin—liver cancer	0.00115	0.00132	CcSEcCtD
Guanabenz—Dry mouth—Doxorubicin—liver cancer	0.00114	0.0013	CcSEcCtD
Guanabenz—Hypotension—Epirubicin—liver cancer	0.00113	0.00129	CcSEcCtD
Guanabenz—Confusional state—Doxorubicin—liver cancer	0.00113	0.00129	CcSEcCtD
Guanabenz—Oedema—Doxorubicin—liver cancer	0.00112	0.00128	CcSEcCtD
Guanabenz—Infection—Doxorubicin—liver cancer	0.00111	0.00127	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Epirubicin—liver cancer	0.0011	0.00126	CcSEcCtD
Guanabenz—Shock—Doxorubicin—liver cancer	0.0011	0.00126	CcSEcCtD
Guanabenz—Nervous system disorder—Doxorubicin—liver cancer	0.0011	0.00125	CcSEcCtD
Guanabenz—Thrombocytopenia—Doxorubicin—liver cancer	0.00109	0.00125	CcSEcCtD
Guanabenz—Tachycardia—Doxorubicin—liver cancer	0.00109	0.00125	CcSEcCtD
Guanabenz—Skin disorder—Doxorubicin—liver cancer	0.00108	0.00124	CcSEcCtD
Guanabenz—Paraesthesia—Epirubicin—liver cancer	0.00108	0.00124	CcSEcCtD
Guanabenz—Dyspnoea—Epirubicin—liver cancer	0.00108	0.00123	CcSEcCtD
Guanabenz—Anorexia—Doxorubicin—liver cancer	0.00106	0.00122	CcSEcCtD
Guanabenz—Dyspepsia—Epirubicin—liver cancer	0.00106	0.00122	CcSEcCtD
Guanabenz—Decreased appetite—Epirubicin—liver cancer	0.00105	0.0012	CcSEcCtD
Guanabenz—Hypotension—Doxorubicin—liver cancer	0.00104	0.00119	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Epirubicin—liver cancer	0.00104	0.00119	CcSEcCtD
Guanabenz—Fatigue—Epirubicin—liver cancer	0.00104	0.00119	CcSEcCtD
Guanabenz—Pain—Epirubicin—liver cancer	0.00103	0.00118	CcSEcCtD
Guanabenz—Constipation—Epirubicin—liver cancer	0.00103	0.00118	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00102	0.00117	CcSEcCtD
Guanabenz—Paraesthesia—Doxorubicin—liver cancer	0.001	0.00115	CcSEcCtD
Guanabenz—Dyspnoea—Doxorubicin—liver cancer	0.000996	0.00114	CcSEcCtD
Guanabenz—Feeling abnormal—Epirubicin—liver cancer	0.000995	0.00114	CcSEcCtD
Guanabenz—Gastrointestinal pain—Epirubicin—liver cancer	0.000987	0.00113	CcSEcCtD
Guanabenz—Dyspepsia—Doxorubicin—liver cancer	0.000983	0.00113	CcSEcCtD
Guanabenz—Decreased appetite—Doxorubicin—liver cancer	0.000971	0.00111	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000964	0.0011	CcSEcCtD
Guanabenz—Fatigue—Doxorubicin—liver cancer	0.000963	0.0011	CcSEcCtD
Guanabenz—Urticaria—Epirubicin—liver cancer	0.000959	0.0011	CcSEcCtD
Guanabenz—Pain—Doxorubicin—liver cancer	0.000955	0.00109	CcSEcCtD
Guanabenz—Constipation—Doxorubicin—liver cancer	0.000955	0.00109	CcSEcCtD
Guanabenz—Abdominal pain—Epirubicin—liver cancer	0.000954	0.00109	CcSEcCtD
Guanabenz—Body temperature increased—Epirubicin—liver cancer	0.000954	0.00109	CcSEcCtD
Guanabenz—Feeling abnormal—Doxorubicin—liver cancer	0.00092	0.00105	CcSEcCtD
Guanabenz—Gastrointestinal pain—Doxorubicin—liver cancer	0.000913	0.00105	CcSEcCtD
Guanabenz—Hypersensitivity—Epirubicin—liver cancer	0.000889	0.00102	CcSEcCtD
Guanabenz—Urticaria—Doxorubicin—liver cancer	0.000887	0.00102	CcSEcCtD
Guanabenz—Body temperature increased—Doxorubicin—liver cancer	0.000883	0.00101	CcSEcCtD
Guanabenz—Abdominal pain—Doxorubicin—liver cancer	0.000883	0.00101	CcSEcCtD
Guanabenz—Asthenia—Epirubicin—liver cancer	0.000866	0.000992	CcSEcCtD
Guanabenz—Pruritus—Epirubicin—liver cancer	0.000854	0.000978	CcSEcCtD
Guanabenz—Diarrhoea—Epirubicin—liver cancer	0.000826	0.000946	CcSEcCtD
Guanabenz—Hypersensitivity—Doxorubicin—liver cancer	0.000823	0.000942	CcSEcCtD
Guanabenz—Asthenia—Doxorubicin—liver cancer	0.000801	0.000917	CcSEcCtD
Guanabenz—Dizziness—Epirubicin—liver cancer	0.000798	0.000914	CcSEcCtD
Guanabenz—Pruritus—Doxorubicin—liver cancer	0.00079	0.000905	CcSEcCtD
Guanabenz—Vomiting—Epirubicin—liver cancer	0.000767	0.000879	CcSEcCtD
Guanabenz—Diarrhoea—Doxorubicin—liver cancer	0.000764	0.000875	CcSEcCtD
Guanabenz—Rash—Epirubicin—liver cancer	0.000761	0.000871	CcSEcCtD
Guanabenz—Dermatitis—Epirubicin—liver cancer	0.00076	0.000871	CcSEcCtD
Guanabenz—Headache—Epirubicin—liver cancer	0.000756	0.000866	CcSEcCtD
Guanabenz—Dizziness—Doxorubicin—liver cancer	0.000739	0.000846	CcSEcCtD
Guanabenz—Nausea—Epirubicin—liver cancer	0.000717	0.000821	CcSEcCtD
Guanabenz—Vomiting—Doxorubicin—liver cancer	0.00071	0.000813	CcSEcCtD
Guanabenz—Rash—Doxorubicin—liver cancer	0.000704	0.000806	CcSEcCtD
Guanabenz—Dermatitis—Doxorubicin—liver cancer	0.000704	0.000806	CcSEcCtD
Guanabenz—Headache—Doxorubicin—liver cancer	0.0007	0.000801	CcSEcCtD
Guanabenz—Nausea—Doxorubicin—liver cancer	0.000663	0.00076	CcSEcCtD
Guanabenz—CYP1A2—Metabolism—GLUL—liver cancer	6.94e-05	0.000548	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—PIK3CG—liver cancer	6.93e-05	0.000547	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—AKT1—liver cancer	6.78e-05	0.000536	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—F2—liver cancer	6.76e-05	0.000534	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—VEGFA—liver cancer	6.74e-05	0.000533	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—PIK3CD—liver cancer	6.71e-05	0.00053	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GSTP1—liver cancer	6.7e-05	0.000529	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NR1H4—liver cancer	6.69e-05	0.000528	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—TGFB1—liver cancer	6.63e-05	0.000523	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—HMOX1—liver cancer	6.61e-05	0.000522	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP2E1—liver cancer	6.6e-05	0.000521	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTA3—liver cancer	6.57e-05	0.000519	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—PIK3CG—liver cancer	6.47e-05	0.000511	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—IL2—liver cancer	6.45e-05	0.000509	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ADAM17—liver cancer	6.42e-05	0.000507	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—PIK3CD—liver cancer	6.27e-05	0.000495	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—TGFB1—liver cancer	6.19e-05	0.000489	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYCS—liver cancer	6.18e-05	0.000488	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PRKCE—liver cancer	6.16e-05	0.000487	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GSTM1—liver cancer	6.16e-05	0.000486	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—KRAS—liver cancer	6.14e-05	0.000485	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—PIK3CD—liver cancer	6.09e-05	0.000481	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GGT1—liver cancer	6.06e-05	0.000479	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GOT1—liver cancer	6.06e-05	0.000479	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—F2—liver cancer	6.05e-05	0.000478	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PSMD10—liver cancer	6.03e-05	0.000477	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PSMA4—liver cancer	6.03e-05	0.000477	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTA4—liver cancer	6.01e-05	0.000475	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	5.88e-05	0.000464	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTA2—liver cancer	5.86e-05	0.000463	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—PIK3CB—liver cancer	5.85e-05	0.000462	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CYP1A1—liver cancer	5.84e-05	0.000461	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IGF2—liver cancer	5.84e-05	0.000461	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PIK3CG—liver cancer	5.79e-05	0.000457	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PRKCE—liver cancer	5.76e-05	0.000455	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—KRAS—liver cancer	5.73e-05	0.000453	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—PIK3CD—liver cancer	5.69e-05	0.000449	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTA1—liver cancer	5.65e-05	0.000447	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—PIK3CA—liver cancer	5.64e-05	0.000445	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NAT2—liver cancer	5.59e-05	0.000442	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—F2—liver cancer	5.49e-05	0.000434	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—VEGFA—liver cancer	5.48e-05	0.000433	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—PIK3CB—liver cancer	5.46e-05	0.000431	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—TP53—liver cancer	5.46e-05	0.000431	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IGF2—liver cancer	5.45e-05	0.000431	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CSF2—liver cancer	5.45e-05	0.000431	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GSTP1—liver cancer	5.44e-05	0.00043	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—MTHFR—liver cancer	5.44e-05	0.00043	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—RAF1—liver cancer	5.44e-05	0.00043	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	5.38e-05	0.000425	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—H2AFX—liver cancer	5.37e-05	0.000424	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—IL2—liver cancer	5.37e-05	0.000424	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—HMOX1—liver cancer	5.37e-05	0.000424	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALDOB—liver cancer	5.36e-05	0.000423	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PPARA—liver cancer	5.34e-05	0.000422	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—PIK3CB—liver cancer	5.31e-05	0.000419	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—PIK3CA—liver cancer	5.27e-05	0.000416	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3CG—liver cancer	5.26e-05	0.000415	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—HRAS—liver cancer	5.22e-05	0.000412	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CRABP1—liver cancer	5.11e-05	0.000404	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—TP53—liver cancer	5.1e-05	0.000403	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CSF2—liver cancer	5.09e-05	0.000402	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PIK3CD—liver cancer	5.09e-05	0.000402	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—RAF1—liver cancer	5.08e-05	0.000401	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—TGFB1—liver cancer	5.03e-05	0.000397	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—H2AFX—liver cancer	5.02e-05	0.000396	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—IL2—liver cancer	5.02e-05	0.000396	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GSTM1—liver cancer	5e-05	0.000395	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—PIK3CB—liver cancer	4.96e-05	0.000392	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—IL2—liver cancer	4.88e-05	0.000385	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—HRAS—liver cancer	4.87e-05	0.000385	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TERT—liver cancer	4.86e-05	0.000384	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP1A1—liver cancer	4.74e-05	0.000375	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PRKCE—liver cancer	4.67e-05	0.000369	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—KRAS—liver cancer	4.66e-05	0.000368	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3CD—liver cancer	4.62e-05	0.000365	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—AKT1—liver cancer	4.61e-05	0.000364	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.6e-05	0.000364	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CG—liver cancer	4.57e-05	0.000361	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—IL2—liver cancer	4.55e-05	0.00036	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TERT—liver cancer	4.54e-05	0.000358	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—HPGDS—liver cancer	4.47e-05	0.000353	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KDR—liver cancer	4.44e-05	0.000351	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.44e-05	0.000351	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PIK3CB—liver cancer	4.44e-05	0.00035	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IGF2—liver cancer	4.43e-05	0.00035	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—MTHFR—liver cancer	4.42e-05	0.000349	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MAPK14—liver cancer	4.41e-05	0.000349	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PPARG—liver cancer	4.41e-05	0.000349	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PPARA—liver cancer	4.34e-05	0.000343	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ESR1—liver cancer	4.33e-05	0.000342	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—AKT1—liver cancer	4.3e-05	0.00034	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—PIK3CA—liver cancer	4.28e-05	0.000338	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—F2—liver cancer	4.28e-05	0.000338	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KDR—liver cancer	4.15e-05	0.000328	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—TP53—liver cancer	4.14e-05	0.000327	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CSF2—liver cancer	4.14e-05	0.000327	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—RAF1—liver cancer	4.13e-05	0.000326	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MAPK14—liver cancer	4.12e-05	0.000326	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—APC—liver cancer	4.09e-05	0.000323	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CG—liver cancer	4.09e-05	0.000323	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—H2AFX—liver cancer	4.08e-05	0.000322	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—IL2—liver cancer	4.07e-05	0.000322	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.05e-05	0.00032	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ESR1—liver cancer	4.04e-05	0.000319	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3CB—liver cancer	4.03e-05	0.000318	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CD—liver cancer	4.02e-05	0.000317	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—F2—liver cancer	4e-05	0.000316	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4e-05	0.000316	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PSMA4—liver cancer	3.98e-05	0.000315	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PSMD10—liver cancer	3.98e-05	0.000315	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ALB—liver cancer	3.97e-05	0.000313	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—HRAS—liver cancer	3.96e-05	0.000313	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GOT2—liver cancer	3.88e-05	0.000306	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—BRAF—liver cancer	3.85e-05	0.000304	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—APC—liver cancer	3.82e-05	0.000302	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CG—liver cancer	3.82e-05	0.000302	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CG—liver cancer	3.71e-05	0.000293	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—IL2—liver cancer	3.7e-05	0.000292	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TERT—liver cancer	3.69e-05	0.000291	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP2E1—liver cancer	3.64e-05	0.000288	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CD—liver cancer	3.6e-05	0.000284	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—BRAF—liver cancer	3.59e-05	0.000284	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PPARG—liver cancer	3.58e-05	0.000283	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—PIK3CA—liver cancer	3.56e-05	0.000282	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SERPINE1—liver cancer	3.56e-05	0.000281	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.53e-05	0.000279	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—KRAS—liver cancer	3.52e-05	0.000278	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CB—liver cancer	3.5e-05	0.000277	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—AKT1—liver cancer	3.5e-05	0.000276	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYCS—liver cancer	3.41e-05	0.000269	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KDR—liver cancer	3.37e-05	0.000266	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CD—liver cancer	3.36e-05	0.000265	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MAPK14—liver cancer	3.35e-05	0.000265	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GOT1—liver cancer	3.34e-05	0.000264	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GGT1—liver cancer	3.34e-05	0.000264	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—PIK3CA—liver cancer	3.33e-05	0.000263	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SERPINE1—liver cancer	3.32e-05	0.000263	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—KRAS—liver cancer	3.29e-05	0.00026	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ESR1—liver cancer	3.29e-05	0.000259	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CD—liver cancer	3.27e-05	0.000258	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—F2—liver cancer	3.25e-05	0.000256	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—PIK3CA—liver cancer	3.24e-05	0.000256	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ALB—liver cancer	3.22e-05	0.000255	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—RAF1—liver cancer	3.21e-05	0.000254	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MTOR—liver cancer	3.14e-05	0.000248	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CB—liver cancer	3.14e-05	0.000248	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—APC—liver cancer	3.11e-05	0.000245	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CG—liver cancer	3.11e-05	0.000245	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—PIK3CA—liver cancer	3.02e-05	0.000239	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTP1—liver cancer	3e-05	0.000237	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—RAF1—liver cancer	3e-05	0.000237	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—HRAS—liver cancer	2.99e-05	0.000237	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—HMOX1—liver cancer	2.96e-05	0.000234	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CDKN1B—liver cancer	2.94e-05	0.000232	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CB—liver cancer	2.93e-05	0.000231	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MTOR—liver cancer	2.93e-05	0.000231	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—BRAF—liver cancer	2.92e-05	0.000231	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—AKT1—liver cancer	2.91e-05	0.00023	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CASP3—liver cancer	2.88e-05	0.000228	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL2—liver cancer	2.88e-05	0.000227	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—IL6—liver cancer	2.87e-05	0.000226	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CB—liver cancer	2.85e-05	0.000225	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CCND1—liver cancer	2.81e-05	0.000222	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—JUN—liver cancer	2.8e-05	0.000221	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—HRAS—liver cancer	2.8e-05	0.000221	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CTNNB1—liver cancer	2.78e-05	0.00022	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTM1—liver cancer	2.76e-05	0.000218	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CDKN1B—liver cancer	2.75e-05	0.000217	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	2.73e-05	0.000216	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MMP9—liver cancer	2.73e-05	0.000215	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—AKT1—liver cancer	2.72e-05	0.000215	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CDKN1A—liver cancer	2.72e-05	0.000215	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	2.7e-05	0.000214	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	2.7e-05	0.000213	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CASP3—liver cancer	2.69e-05	0.000213	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL2—liver cancer	2.69e-05	0.000213	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—IL6—liver cancer	2.68e-05	0.000211	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—KRAS—liver cancer	2.67e-05	0.000211	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MAPK8—liver cancer	2.65e-05	0.000209	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—AKT1—liver cancer	2.64e-05	0.000209	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CCND1—liver cancer	2.62e-05	0.000207	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP1A1—liver cancer	2.62e-05	0.000207	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—JUN—liver cancer	2.62e-05	0.000207	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CTNNB1—liver cancer	2.6e-05	0.000205	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MMP9—liver cancer	2.55e-05	0.000201	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CDKN1A—liver cancer	2.54e-05	0.0002	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MAPK8—liver cancer	2.48e-05	0.000196	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—AKT1—liver cancer	2.47e-05	0.000195	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	2.46e-05	0.000194	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—VEGFA—liver cancer	2.45e-05	0.000193	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—MTHFR—liver cancer	2.44e-05	0.000193	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—RAF1—liver cancer	2.44e-05	0.000193	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—STAT3—liver cancer	2.42e-05	0.000191	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PPARA—liver cancer	2.39e-05	0.000189	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MTOR—liver cancer	2.38e-05	0.000188	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	2.38e-05	0.000188	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—VEGFA—liver cancer	2.29e-05	0.000181	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—HRAS—liver cancer	2.27e-05	0.000179	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—STAT3—liver cancer	2.26e-05	0.000179	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MYC—liver cancer	2.25e-05	0.000178	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TGFB1—liver cancer	2.25e-05	0.000177	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	2.23e-05	0.000176	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	2.21e-05	0.000174	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CASP3—liver cancer	2.19e-05	0.000173	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL2—liver cancer	2.19e-05	0.000173	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—IL6—liver cancer	2.17e-05	0.000172	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.15e-05	0.00017	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PIK3CA—liver cancer	2.14e-05	0.000169	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCND1—liver cancer	2.13e-05	0.000168	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—JUN—liver cancer	2.13e-05	0.000168	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	2.11e-05	0.000167	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MYC—liver cancer	2.1e-05	0.000166	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TGFB1—liver cancer	2.1e-05	0.000166	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KRAS—liver cancer	2.08e-05	0.000164	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MMP9—liver cancer	2.07e-05	0.000163	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	2.06e-05	0.000163	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CG—liver cancer	2.05e-05	0.000162	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MAPK8—liver cancer	2.01e-05	0.000159	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—AKT1—liver cancer	2.01e-05	0.000158	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PPARG—liver cancer	1.98e-05	0.000156	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KRAS—liver cancer	1.94e-05	0.000154	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	1.91e-05	0.000151	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—VEGFA—liver cancer	1.86e-05	0.000147	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TP53—liver cancer	1.85e-05	0.000146	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—STAT3—liver cancer	1.84e-05	0.000145	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CD—liver cancer	1.8e-05	0.000142	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	1.79e-05	0.000141	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALB—liver cancer	1.78e-05	0.000141	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HRAS—liver cancer	1.77e-05	0.00014	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—AKT1—liver cancer	1.74e-05	0.000138	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PIK3CA—liver cancer	1.73e-05	0.000137	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TP53—liver cancer	1.73e-05	0.000136	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MYC—liver cancer	1.71e-05	0.000135	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TGFB1—liver cancer	1.7e-05	0.000135	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL6—liver cancer	1.69e-05	0.000134	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HRAS—liver cancer	1.65e-05	0.000131	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL6—liver cancer	1.58e-05	0.000125	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KRAS—liver cancer	1.58e-05	0.000125	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CB—liver cancer	1.57e-05	0.000124	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—AKT1—liver cancer	1.56e-05	0.000123	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—AKT1—liver cancer	1.46e-05	0.000115	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	1.45e-05	0.000115	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—AKT1—liver cancer	1.42e-05	0.000112	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TP53—liver cancer	1.4e-05	0.000111	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HRAS—liver cancer	1.34e-05	0.000106	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL6—liver cancer	1.28e-05	0.000101	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—AKT1—liver cancer	1.19e-05	9.36e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PIK3CA—liver cancer	9.58e-06	7.56e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—AKT1—liver cancer	7.82e-06	6.18e-05	CbGpPWpGaD
